(NYSE: NUVB) Nuvation Bio's forecast annual revenue growth rate of 194.76% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 87.9%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.62%.
Nuvation Bio's revenue in 2025 is $10,957,000.On average, 2 Wall Street analysts forecast NUVB's revenue for 2025 to be $9,352,127,895, with the lowest NUVB revenue forecast at $7,179,548,794, and the highest NUVB revenue forecast at $11,524,706,997. On average, 2 Wall Street analysts forecast NUVB's revenue for 2026 to be $49,751,551,036, with the lowest NUVB revenue forecast at $47,990,690,135, and the highest NUVB revenue forecast at $51,512,411,937.
In 2027, NUVB is forecast to generate $97,614,642,555 in revenue, with the lowest revenue forecast at $97,614,642,555 and the highest revenue forecast at $97,614,642,555.